INDIRECT TREATMENT COMPARISONS OF NIVOLUMAB VERSUS REGORAFENIB, CABOZANTINIB AND BEST SUPPORTIVE CARE AFTER TREATMENT WITH SORAFENIB FOR HEPATOCELLULAR CARCINOMA

被引：5
|
作者：
Roskell, N. [1 ]
Gregory, J. [1 ]
Wisniewski, T. [2 ]
Thompson, G. J. [2 ]
De la Cruz, C. [3 ]
机构：
[1] BresMed Hlth Solut, Sheffield, S Yorkshire, England
[2] Bristol Myers Squibb, Princeton, NJ USA
[3] Bristol Myers Squibb Ltd, Princeton, NJ USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.099
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN17
引用
收藏
页码：S17 / S18
页数：2
相关论文
共 50 条
  • [1] Regorafenib improves survival after sorafenib treatment in patients with recurrent hepatocellular carcinoma after liver transplantation, compared to best supportive care
    Iavarone, Massimo
    Invernizzi, Federica
    Zavaglia, Claudio
    Sanduzzi Zamparelli, Marco
    Fraile, Miguel
    Czauderna, Carolin
    Di Costanzo, Giuseppe
    Bhoori, Sherrie
    Pinter, Matthias
    Manini, Matteo Angelo
    Amaddeo, Giuliana
    Fernandez, Ainhoa
    Pinero, Federico
    Blanco Rodriguez, Maria Jose
    Anders, Maria Margarita
    Aballay Soteras, Gabriel Alejandro
    Villadsen, Gerda Elisabeth
    Cesarini, Lucia
    Mazza, Stefano
    Diaz-Gonzalez, Alvaro
    Gonzalez Dieguez, Maria Luisa
    Tortora, Raffaella
    Weinmann, Arndt
    Mazzaferro, Vincenzo
    Romero, Mario
    Crespo, Gonzalo
    Regnault, Helene
    De Giorgio, Massimo
    Varela, Maria
    Donato, Maria Francesca
    Worns, Marcus-Alexander
    Bruix, Jordi
    Lampertico, Pietro
    Reig, Maria
    [J]. JOURNAL OF HEPATOLOGY, 2020, 73 : S103 - S104
  • [2] Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
    Kuo, Yuan-Hung
    Yen, Yi-Hao
    Chen, Yen-Yang
    Kee, Kwong-Ming
    Hung, Chao-Hung
    Lu, Sheng-Nan
    Hu, Tsung-Hui
    Chen, Chien-Hung
    Wang, Jing-Houng
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [3] Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
    Lee, Cheol-Hyung
    Lee, Yun Bin
    Kim, Minseok Albert
    Jang, Heejoon
    Oh, Hyunwoo
    Kim, Sun Woong
    Cho, Eun Ju
    Lee, Kyung-Hun
    Lee, Jeong-Hoon
    Yu, Su Jong
    Yoon, Jung-Won
    Kim, Tae-You
    Kim, Yoog Jun
    [J]. CLINICAL AND MOLECULAR HEPATOLOGY, 2020, 26 (03) : 328 - 339
  • [4] Regorafenib versus cabozantinib as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: Matching-adjusted indirect comparison analysis
    Gardini, A. Casadei
    Rimassa, L.
    Yoo, C.
    Lonardi, S.
    Cucchetti, A.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S105 - S105
  • [5] Second-line treatment with nivolumab, cabozantinib, regorafenib, or best supportive care in patients with advanced hepatocellular carcinoma: analysis at a Hispanic-majority NCI-designated cancer center
    Xia, Jeffrey
    Gelfond, Jonathan
    Arora, Sukeshi Patel
    [J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (06) : 2943 - 2951
  • [6] REGORAFENIB VERSUS NIVOLUMAB FOR HEPATOCELLULAR CARCINOMA PATIENTS WHO EXPERIENCED SORAFENIB TREATMENT FAILURE: A PROPENSITY SCORE ANALYSIS
    Lee, Cheol-Hyung
    Lee, Yun Bin
    Kim, Minseok Albert
    Jang, Heejoon
    Kim, Sun Woong
    Cho, Eun Ju
    Lee, Jeong-Hoon
    Yu, Su Jong
    Yoon, Jung-Hwan
    Kim, Yoon Jun
    [J]. HEPATOLOGY, 2019, 70 : 212A - 213A
  • [7] TREATMENT OF RECURRENT HEPATOCELLULAR CARCINOMA AFTER LIVER TRANSPLANTATION: REGORAFENIB PROVIDES SURVIVAL BENEFIT AS COMPARED TO BEST SUPPORTIVE CARE
    Iavarone, Massimo
    Invernizzi, Federica
    Mazza, Stefano
    Zavaglia, Claudio
    Czauderna, Carolin
    Sanduzzi Zamparelli, Marco
    Bhoori, Sherrie
    Amaddeo, Giuliana
    Manini, Matteo
    Fraile Lopez, Miguel
    Anders, Margarita
    Pinter, Matthias
    Blanco Rodriguez, Maria Jose
    Romero Cristobal, Mario
    Aballay Soteras, Gabriel
    Pinero, Federico
    Villadsen, Gerda Elisabeth
    Weinmann, Arndt
    Crespo, Gonzalo
    Mazzaferro, Vincenzo
    Regnault, Helene
    De Giorgio, Massimo
    Gonzalez Dieguez, Maria Luisa
    Donate, Maria Francesca
    Varela, Maria
    Worns, Marcus
    Bruix, Jordi
    Lampertico, Pietro
    Reig, Maria
    [J]. HEPATOLOGY, 2019, 70 : 210A - 212A
  • [8] Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma
    Kim, Yuna
    Lee, Jae Seung
    Lee, Hye Won
    Kim, Beom Kyung
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Goh, Myung Ji
    Kang, Wonseok
    Kim, Seung Up
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2023, 35 (02) : 191 - 197
  • [9] Regorafenib Versus Nivolumab After Sorafenib Failure: Real-World Data in Patients With Hepatocellular Carcinoma
    Choi, Won-Mook
    Choi, Jonggi
    Lee, Danbi
    Shim, Ju Hyun
    Lim, Young-Suk
    Lee, Han Chu
    Chung, Young-Hwa
    Lee, Young-Sang
    Park, Sook Ryun
    Ryu, Min-Hee
    Ryoo, Baek-Yeol
    Lee, So Jung
    Kim, Kang Mo
    [J]. HEPATOLOGY COMMUNICATIONS, 2020, 4 (07) : 1073 - 1086
  • [10] Regorafenib versus nivolumab after sorafenib failure: real-world data in patients with hepatocellular carcinoma
    Choi, Won-Mook
    Choi, Jonggi
    Shim, Ju Hyun
    Lim, Young-Suk
    Lee, Han Chu
    Kim, Kang Mo
    [J]. JOURNAL OF HEPATOLOGY, 2020, 73 : S39 - S39
12345